Evidence map›Paper›PMID 35630524›Full record

ArticleMolecules (Basel, Switzerland)2022

The Chemical Constituents of Diaphragma Juglandis Fructus and Their Inhibitory Effect on α-Glucosidase Activity.

Jinyan Tan, Yangang Cheng, Shihui Wang, Jianli Li, Haiqin Ren, Yuanbiao Qiao, Qingshan Li, Yingli Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jinyan TanShanxi Modern Chinese Medicine Engineering Laboratory, Shanxi University of Chinese Medicine, Jinzhong 030619, China.ORCID 0000-0003-4567-8985
Yangang ChengShanxi Modern Chinese Medicine Engineering Laboratory, Shanxi University of Chinese Medicine, Jinzhong 030619, China.
Shihui WangShanxi Modern Chinese Medicine Engineering Laboratory, Shanxi University of Chinese Medicine, Jinzhong 030619, China.
Jianli LiShanxi Modern Chinese Medicine Engineering Laboratory, Shanxi University of Chinese Medicine, Jinzhong 030619, China.
Haiqin RenShanxi Modern Chinese Medicine Engineering Laboratory, Shanxi University of Chinese Medicine, Jinzhong 030619, China.
Yuanbiao QiaoShanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation, Shanxi University of Chinese Medicine, Jinzhong 030619, China.
Qingshan LiShanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation, Shanxi University of Chinese Medicine, Jinzhong 030619, China.
Yingli WangShanxi Modern Chinese Medicine Engineering Laboratory, Shanxi University of Chinese Medicine, Jinzhong 030619, China.

Funding

"1331 Project" Quality and Efficiency Improvement Construction Plan Project 〔2021〕No. 4Open Fund of Shanxi Key Laboratory of Innovative Drug for the Treatment of Serious Diseases Basing on the Chronic Inflammation, Shanxi University of Chinese Medicine 2021sxcxyw10Shanxi Provincial Health Commission 2020094
6 · The paper itself

Abstract

In our current investigation, 37 constituents (

Indexed as

alpha-GlucosidasesGlycoside Hydrolase InhibitorsCarbohydrate MetabolismFlavonoidsFruitalpha-GlucosidasesFlavonoidsGlycoside Hydrolase Inhibitorsbicyclic neomegastigmaneflavonoidsmegastigmanesphenylpropanoidswalnutα-glucosidase inhibition activity

Identifiers

PMID35630524
PMCPMC9143591

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.